期刊
PEDIATRIC PULMONOLOGY
卷 56, 期 10, 页码 3283-3292出版社
WILEY
DOI: 10.1002/ppul.25610
关键词
CHNC; chronic lung disease; dexamethasone; hydrocortisone; prematurity
资金
- National Institute of Diabetes and Digestive and Kidney Diseases [K08DK125735]
- National Institute of Child Health and Human Development [K23HD091362]
- National Heart, Lung, and Blood Institute [K23HL136525]
Among preterm infants treated with systemic corticosteroids, later initiation of treatment was associated with a higher likelihood of developing Grade 2 or 3 BPD compared to earlier treatment.
Objective To evaluate the association between the time of first systemic corticosteroid initiation and bronchopulmonary dysplasia (BPD) in preterm infants. Study design A multi-center retrospective cohort study from January 2010 to December 2016 using the Children's Hospitals Neonatal Database and Pediatric Health Information System database was conducted. The study population included preterm infants We identified 598 corticosteroid-treated infants (median gestational age 25 weeks, median birth weight 760 g). Of these, 47% (280 of 598) were first treated at 8-21 days, 25% (148 of 598) were first treated at 22-35 days, 14% (86 of 598) were first treated at 36-49 days, and 14% (84 of 598) were first treated at >50 days. Infants first treated at 36-49 days (aOR 2.0, 95% CI 1.1-3.7) and >50 days (aOR 1.9, 95% CI 1.04-3.3) had higher independent odds of developing Grade 2 or 3 BPD when compared to infants treated at 8-21 days after adjusting for birth characteristics, admission characteristics, center, and co-morbidities. Conclusions Among preterm infants treated with systemic corticosteroids in routine clinical practice, later initiation of treatment was associated with a higher likelihood to develop Grade 2 or 3 BPD when compared to earlier treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据